.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BJ06_Semaglutide.Semaglutide_1 .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BJ06_Semaglutide.Semaglutide_1| name: | Semaglutide_1 |
| ATC code: | A10BJ06_1 | route: | oral |
| n-compartments | 2 |
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of type 2 diabetes mellitus and chronic weight management. It is currently approved for clinical use in both oral and subcutaneous injectable formulations.
Pharmacokinetic parameters reported for healthy subjects after oral administration of semaglutide tablets.
Overgaard, RV, et al., & Kildemoes, RJ (2021). Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Clinical pharmacokinetics 60(10) 1335–1348. DOI:10.1007/s40262-021-01025-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/33969456
Yang, XD, & Yang, YY (2024). Clinical Pharmacokinetics of Semaglutide: A Systematic Review. Drug design, development and therapy 18 2555–2570. DOI:10.2147/DDDT.S470826 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38952487
Clements, JN, et al., & Gambill, K (2021). Pharmacokinetics and Clinical Implications of Oral Semaglutide for Type 2 Diabetes Mellitus. Clinical pharmacokinetics 60(2) 153–163. DOI:10.1007/s40262-020-00951-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33108617